Background Anti-β2-glycoprotein-I (anti-β2GPI) were demonstrated to be pathogenic in the
antiphospholipid syndrome (APS). However, they can be detected in patients with no …

Objective It has been suggested that only antibodies against domain 1 (D1) of β2‐
glycoprotein I (β2GPI) are pathogenic and diagnostic. The role of antibodies against other …

Objective: To evaluate avidity of IgG anti-β2-glycoprotein I antibodies (anti-β2-GPI) in
patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in …

Objective To examine the prevalence of isolated IgA anti–β2‐glycoprotein I (anti‐β2GPI)
positivity and the association of these antibodies, and a subgroup that bind specifically to …

Abstract Beta-2 glycoprotein I (β 2 GPI) is the main antigenic target for antiphospholipid
antibodies (aPL), the serological markers of antiphospholipid syndrome (APS). Domain I (DI) …

Antibodies against β2 glycoprotein I (anti-β2GPI) have been identified as the main
pathogenic autoantibody subset in anti-phospholipid syndrome (APS); the most relevant …

Objective To determine whether serum β2‐glycoprotein I antibody (anti‐β2GPI) detection
improves identification of pediatric subjects at risk for antiphospholipid syndrome (APS) …

Objective To determine the frequencies at which either a valine or leucine occurs at position
247 in the β2‐glycoprotein I (β2GPI) gene of normal individuals of the Caucasian, African …

Abstract Objectives. β 2-Glycoprotein I (β 2GPI) exon 7 polymorphism leads to a valine–
leucine amino acid exchange at position 247 in domain 5 of β 2GPI, between the …

Patients diagnosed with the antiphospholipid syndrome typically suffer from vascular
thrombosis, pregnancy morbidity, or a combination of the two. Due to the high prevalence of …